| 目的 了解尿激酶型纤溶酶原激活剂（uPA）与膀胱肿瘤恶性程度及浸润深度之间的关系。 方法 采用酶联免疫吸附实验（ELISA）检测51例膀胱移行细胞癌病人术前、术后静脉血及肿瘤组织uPA含量。 结果 G3肿瘤组织uPA含量明显高于G1和G2（P均＜0.01），G1与G2间uPA差异无显著性；浸润癌肿瘤组织uPA含量明显高于表浅肿瘤组织（P＜0.05）。病人术前及术后静脉血uPA含量与正常人静脉血uPA含量差异无显著性。 结论 肿瘤组织uPA含量可以反映膀胱肿瘤的恶性程度和肿瘤浸润深度。
Urokinase-type plasminogen activator (uPA) in the neoplastic tissue and peripheral blood of bladder cancer patients
YANG Jinyi,LI Shao,ZhOU Rongxiang,et al.
Department of Urology,the Affiliated Hospital of Binzhou Medical College, Shandong 256603
Abstract Objective To study the uPA level in the neoplastic tissue and peripheral blood of bladder cancer patients. Methods 51 cases of transitional cell bladder cancer were studied by means of enzyme-linked immunosorbent assay (ELISA). Results uPA content in neoplastic tissue of grade Ⅲ tumors was obviously higher than that in grade Ⅱ or grade Ⅰ tumors (P＜0.01) whereas there was no significant difference between grade Ⅰ and grade Ⅱ tumors.uPA content was also higher in the invasive tumors than the superficial ones (P＜0.05).There was no significant difference in peripheral blood uPA between bladder cancer patients and normal subjects. Conclusions uPA content in the neoplastic tissue might be a useful index of the degree of malignancy and invasiveness of transitional cell bladder cancinoma.
Key words Bladder neoplasms Carcinoma Urokinase
近年来的研究表明，尿激酶型纤溶酶原激活剂（uPA）与肿瘤的侵袭和转移密切相关。我们应用酶联免疫吸附实验（ELISA）检测膀胱移行细胞癌患者血及肿瘤组织中uPA含量，以探讨uPA在膀胱癌中的临床应用价值。
材料和方法
一、标本收集
1996年8月～1998年5月本院收治膀胱癌51例，病理证实均为移行细胞癌。男38例，女13例，年龄24～72岁，平均61岁。按UICC标准分浅表性（PTa～PT1）36例，浸润性（PT2～PT4）15例。按WHO标准G1 14例，G2 24例，G3 13例。51例患者中23例行经尿道电切术，19例行膀胱部分切除或加输尿管再植术，9例行全膀胱切除术。所有病人术前及术后1周抽取前臂静脉血2ml，离心后-20℃保留血清，另留取10例正常人血清做对照。经尿道电切前用活检钳钳取肿瘤标本及肉眼观察正常膀胱粘膜，开放手术待标本切下后，立即取肿瘤标本及距肿瘤边缘2cm以外肉眼观正常之膀胱粘膜。另取非膀胱癌患者膀胱粘膜10例，其中前列腺增生症7例，膀胱颈梗阻3例，平均年龄68岁。标本取出后立即-70℃冰冻保存。 |
